2 Information about ceritinib
|
Marketing authorisation indication |
Ceritinib (Zykadia, Novartis) as monotherapy is indicated for 'the first-line treatment of adult patients with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer'. |
|---|---|
|
Dosage in the marketing authorisation |
Ceritinib is taken orally, without food, at the same time each day. The recommended dose is 750 mg once daily. The summary of product characteristics recommends that treatment should continue as long as clinical benefit is observed. |
|
Price |
A 30‑day supply of ceritinib (150 capsules) costs £4,923.45 (excluding VAT; British national formulary [BNF] online [accessed October 2017]). The company has agreed a patient access scheme with the Department of Health. This scheme provides a simple discount to the list price of ceritinib, with the discount applied at the point of purchase or invoice. The level of the discount is commercial in confidence. The Department of Health considered that this patient access scheme does not constitute an excessive administrative burden on the NHS. |